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Abstract: Metabolic bone disease is a frequent co-morbidity in newly diagnosed adults with
celiac disease (CD), an autoimmune disorder triggered by the ingestion of dietary gluten. This
systematic review of studies looked at the efficacy of the gluten-free diet, physical activity,
nutrient supplementation, and bisphosphonates for low bone density treatment. Case control
and cohort designs were identified from PubMed and other academic databases (from 1996
to 2015) that observed newly diagnosed adults with CD for at least one year after diet
treatment using the dual-energy x-ray absorptiometry (DXA) scan. Only 20 out of 207 studies
met the inclusion criteria. Methodological quality was assessed using the Strengthening of the
Reporting of Observational Studies in Epidemiology (STROBE) statement checklist.
Gluten-free diet adherence resulted in partial recovery of bone density by one year in all studies,
and full recovery by the fifth year. No treatment differences were observed between the
gluten-free diet alone and diet plus bisphosphonates in one study. For malnourished patients,
supplementation with vitamin D and calcium resulted in significant improvement. Evidence
for the impact of physical activity on bone density was limited. Therapeutic strategies aimed
at modifying lifestyle factors throughout the lifespan should be studied.
Keywords: celiac disease; gluten; osteoporosis; diet; physical activity; bone density;
nutrient deficiency
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1. Introduction
Celiac disease (CD) is triggered in genetically susceptible individuals by dietary gluten that results in
intestinal damage and occurs in 1% of the population in Europe and the United States [1]. Approximately
75% of newly diagnosed patients with celiac disease have low bone mineral density (BMD). And when
matched by age and gender to a non-affected population, celiac patients have a 40% greater risk for bone
fracture [2]. Even with a silent or extra-intestinal presentation such as dermatitis herpetiformis or dementia,
low bone mass is frequently found [3–5]. One-third of newly diagnosed cases are over 60 years of age which
coincides with a period of an increased risk of falls only worsened by the presence of co-morbidities [6,7].
Women with celiac disease have a much higher rate of fractures during the 10 year period prior to diagnosis
and 5 years afterward [8]. The cumulative effects of gluten-induced inflammation, treatment delay, and
malabsorption result in lower bone density and bone fragility.
The most effective treatment for celiac disease and related co-morbidities, the gluten-free diet (GFD),
is without dispute in the literature. Yet, improvements in BMD after treatment can take as long as two to
five years after mucosal recovery [9–12] Nutritional deficiencies are common during the initial year of
treatment for celiac disease, but little data exists on adult micronutrient status and bone mineral density in
this population beyond calcium and vitamin D status [13–16].
The objective of this systematic review is to examine whether a GFD, alone or in combination with
other interventions, leads to bone mineral recovery in newly diagnosed adults with celiac disease. A
second objective is to identify gaps in the literature that would inform the design of future clinical trials
and health intervention studies.
2. Methods
2.1. Criteria for Considering Studies for this Review
The literature search was limited to English-language articles on untreated and treated adults with
celiac disease observed for one year or more. Studies that were exclusively silent or asymptomatic were
included if they were part of the sample due to their known bone mineral status. The types of studies
considered were cohort, case-control, and randomized controlled designs. Case report and case series
were excluded from the analysis. Studies that included co-morbid conditions, such as diabetes or primary
hyperparathyroidism, were excluded. Randomized controlled trials and interventions that identified
the dose, frequency, type of nutrition supplementation, and physical activity were sought.
2.2. Search Strategy for Identification of Studies
A keyword search was accomplished in PubMed (January 1996 to April 2015); Embase; CINAHL
plus full text; EBSCO; Scopus; ProQuest Dissertations and Theses, and University of Connecticut library
resources (HOMER). The MEDLINE search strategy keywords were “celiac disease” [MeSH]) AND
(“bone mineral density” OR “osteoporosis” OR “bone density”) AND (“exercise” OR “physical
activity”) AND (“nutrition” OR “gluten-free”) in publication title, abstract, or full-text. The inclusion
criteria for this effort were studies with a focus on the treatment of newly diagnosed adults with celiac
disease that reported the dependent variable as bone mineral density (BMD) as a dual-energy X-ray
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absorptiometry (DXA) T-score at baseline and at the annual assessment. Treatment modalities sought
included gluten-free diet, physical activity, or vitamin and mineral supplementation. Case studies and
papers that did not report DXA data at baseline were excluded.
Key article reference lists were hand searched from the Cochrane database of systematic reviews,
meta-analyses, and review articles, as well as papers in (Bone, Gut, Osteoporosis International, and
American Journal of Gastroenterology). Finally, journal review articles, and meta-analyses for non-celiac
studies of low BMD were reviewed.
2.3. Quality Assessments
The clinical trials meeting the criteria are listed in Table 1. Methodological quality was assessed using
the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology Statement)
recommendations using separate checklists for conference abstracts, case control studies, cohort studies,
and cross-sectional studies [17]. The use of a qualitative assessment using a percentage system to
categorize the studies as proposed by other authors proved to be unreasonable because of the age of some
of the papers, published years before the STROBE recommendations [18]. The final system used was a
combination of STROBE (50%–80% fulfilled) and whether missing items left the reader questioning
eligibility criteria or bias in the results reported. After 2008, most of the papers fell into the “A”
quality category.
2.4. Overview of Studies
Three categories of study were identified: GFD; GFD and nutritional supplement; GFD and
bisphosphonates; and a combination of GFD, supplement and exercise. The outcome measures in
selected articles included: DXA (femoral neck, trochanter and lumbar spine), ligand of receptor activator
of NFκB (RANKL) /osteoprotegerin (OPG) ratio, adherence to a GFD, and physical activity level. The
clinical trials meeting the criteria are listed in Table 1.
3. Results
After the initial screening of articles and abstracts from the initial search strategy, a total of 180 articles
were retrieved. The systematic process yielded 20 reports (Figure 1). During the period of this review
there was an evolution in diagnosis and classification of CD with greater acceptance of serology test
results for screening and monitoring in adults, combined with biopsy for diagnosis [19–21]. These
developments made study comparisons more difficult because of the clinical heterogeneity between
subjects with little or no villous atrophy.
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Table 1. Studies meeting search criteria.

Author Publication Year

Summary
Title

Design

Treatment

Participants

Results

Quality

Gender (M/F) Classical CD 9/10,
Corazza (1996) [22]

Reversal of osteopenia with diet in adult

Prospective,

coeliac disease

case-control

GFD

Mdn age =

26.5 years, Subclinical

untreated 11/14, Mdn age = 28.5 years,

GFD normalizes BMD in subclinical, but not
classical CD.

B

Control 13/15 (Mdn age = 28)
Influence
Valdimarsson (1996) [23]

of

pattern

of

clinical

After one year taking a GFD bone mineral

presentation and of gluten-free diet on

Prospective,

bone mass and metabolism in adult

case-control

GFD

n = 63, Age range = 17–79 years,

density increased at all sites (p < 0.01). Seven

M/F = 28/35

patients with dermatitis herpetiformis had

coeliac disease

normal BMD, vitamin D & PTH status

Effect of a gluten free diet on osteopenia
McFarlane (1996) [24]

in adults with newly diagnosed coeliac

Prospective, cohort

GFD

disease
Effects of dietary treatment on bone
Ciacci (1997) [25]

mineral density in adults with celiac
disease: factors predicting response

Prospective,
case-control

Effect of treatment on bone mass,
Mautalen (1997) [26]

mineral

metabolism,

B

and

body

composition in untreated celiac disease

GFD & calcium

GFD or GFD plus calcium
Prospective, RCT

(1 g day−1) & vitamin D
(32,000 IU week−1)

patients.

n = 21 M/F = 14/7, Mean age = 49.7
years (31.0 to 66.1)
Gender

(M/F)

11/30

Almost half of subjects had osteoporosis. After
1 year of treatment there was significant

B

improvement in BMD
n

=

41,

M/F = 11/30, Mean age = 34.3

Mean BMD (g cm−2) significantly improved by
one year after GFD treatment in most, but not

B

all subjects.

n = 41, M/F = 11/30, Mean age = 34.3

Mean BMD (g cm−2) significantly improved by

years

one year in most but not all subjects.

B

n = 28 newly diagnosed CD patients
(9 men, 19 women) recruited from 1990
Kemppainen (1999) [27]

Bone recovery after a gluten-free diet: a
5-year follow-up study

Prospective, cohort

GFD

to 1991. 6 patients withdrew. Women

Bone disease “cured” by 5 years; with most of

Age = 44.1 ± 13.6 and Men Age = 48.6

improvement in the first 12 months.

± 12.3 Compliance with the GFD was
good: 96% at 1 year and 82% at 5 years.

A

Nutrients 2015, 7

3351
Table 1. Cont.

Author Publication Year

Valdimarsson (1999) [28]

Summary
Title

Design

Low circulating insulin-like growth

Prospective,

factor 1 in coeliac disease and its

case-control,

relation to bone mineral density

longitudinal

Treatment

Participants
n = 29 CD, Mean age = 41 years,

GFD

(range 21–66), M/F 8/21, n = 29
controls, age and gender matched

The effects of 1-year gluten
metabolism and nutritional status in

Prospective, cohort

GFD

newly-diagnosed adult coeliac

n = 86 newly diagnosed CD,
M/F = 22/64, mean age M/F = 29/29

disease patients

Taranta (2004) [30]

BMD and circulating IGF-1 levels are low in
adults with untreated CD.

Quality

A

GFD leads to significant increase in BMD and

withdrawal on bone mass, bone
Sategna-Guidetti (2000) [29]

Results

IGF-1 levels in postmenopausal women and
in patients with incomplete mucosal recovery.

A

Folic acid, albumin and pre-albumin serum
levels low for those with incomplete recovery.

Imbalance of osteoclastogenesis-

Prospective,

regulating factors in patients with

case-control,

celiac disease

longitudinal

GFD

n = 25 treated, n = 17 untreated,

Results suggest that bone loss in CD caused

n = 17 controls, Treated group

by a cytokine imbalance directly affecting

mean age = 35.7 ± 7.9 years,

osteoclastogenesis. RANKL/osteoprotegerin

Untreated mean age = 43 ± 9.9

A

ratio was increased in patients not on the GFD.
GFD induced increase of BMD at femur

PO.7 Physical activity does not
Bucci (2008) [31]

influence bone mass density in

Prospective cohort

Unrestricted and GFD

celiac adult patients

n = 57 adults, age range = 18–45,

independently of the amount of reported

CD enrolled, 38 completed the study

physical activity, but difference was not

protocol after a 24 months of GFD.

significant from baseline to follow-up in the

High rate of dropout (33%).

low BMD group. PA was did not differ from

B

baseline at 24 months.
n = 27 (mild enteropathy ),mean age
Gastrointestinal symptoms, quality
Kurppa (2010) [32]

of life and bone mineral density in

Prospective,

mild enteropathic coeliac disease: A

cohort study

prospective clinical trial.

GFD

(16–70); n = 46 (celiac), mean age 46

Osteoporosis or osteopenia was detected in

(16–70); BMD measured in n = 19

58% of subjects in the mild enteropathy group

(normal villi), n = 39 (villus atrophy);

and there was a trend towards improved bone

n = 110 non-celiac controls mean age

mineral density after the treatment.

49 (24–87)

B
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Author Publication Year

Summary
Title

Design

Treatment

Participants

Results

Quality

Women diagnosed with CD because of overt
malabsorption
S2044 effect of a gluten free diet on
Papamichael (2010) [33]

bone mineral density in patients

Prospective cohort

with celiac disease.

GFD/Vitamin D

n = 22 CD patients, M/F = 7/15,

and calcium

mean age = 33 (21–69) years

had

osteoporosis

despite

supplementation with calcium and vitamin D.
At baseline 10 female and all male patients had

B

osteopenia. After 1 year 3 osteoporotic women
had osteopenia, while the remaining 19
patients had a normal BMD.
Increase in BMD, BMI, and abdominal fat on

Longitudinal evaluation of bone
Duerksen & Leslie (2011) [34]

mineral density and body

Retrospective

composition in patients with

cohort, database

Age > 40 years at baseline and testing for
GFD

CD within 6 mo of baseline DXA test Groups:
37 (seropositive)/214 (controls)

positive celiac serology

GFD.

Seropositive

versus

seronegative

individuals had greater increases in mean spine
BMD (4.6%/year vs. 0.7% spine, p < 0.0001),

A

hip BMD (3.0%/year vs. 0.2% year−1 hip,
p < 0.0001).
Screen detected older celiac may suffer from

Clinical benefit of gluten-free diet
Vilppula (2011) [35]

in screen-detected older celiac
disease patients.

Prospective,
cohort study

GFD

n = 35, Median age = 61 years
(range 52–76), M/F = 15/20

subclinical malnutrition, GI symptoms or bone
disease. Significant difference between pre &

A

post-treatment femoral and lumbar spine Z
scores.
Prevalence of osteoporosis was 67% in older

Celiac disease in elderly adults:
Casella (2012) [36]

clinical, serological, and
histological characteristics and the
effect of a gluten-free diet

M: n = 16(A), n = 306(B) F: n = 43(A),

Retrospective,
cohorts grouped
by age

GFD

n = 860(B) Mean Age at diagnosis, µ ± SD:
70.1 ± 4.3 (65–83 years), 35.2 ± 10.6
(18–64 years)

and 14% in younger male participants and 70%
in older and 9% in younger female participants
(p < 0.001). Lumbar-sacral and femoral
T-scores increased significantly during GFD in
pooled results of 48 older and younger
participants studied before and during GFD.

A
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Author Publication Year

Summary
Title

Design

Treatment

Participants

Results

Quality

Improvement in BMD on GFD was

Passananti (2012) [37]

Bone mass in women with celiac

Prospective,

disease: role of exercise and gluten-

cohort,

free diet

longitudinal

48 women of 2-year FU group
GFD

(Mean age = 35.1 ± 8.7 years) and
47 women of 5-year FU group
(Mean age = 35.1 ± 11.3 years)

significant after 2 years; physical activity was
frequently low. No significant relationship
was observed between the BMD for 2-year

B

FU and 5-year FU and level of physical
activity at diagnosis (p > 0.05) for the lumbar
spine and for the proximal femur).
Adult CD subjects treated with GFD for

n = 19 treated, n = 16 untreated and
Szymczak (2012) [38]

Low bone mineral density in adult
patients with coeliac disease

Prospective,
case-control,
longitudinal

GFD plus calcium &
alfacalcidol (vitamin D)

36 controls, second study of
supplementation and GFD
n = 35 CD group M/F = 6/29,
Mean age 41.5 ± 13.6 years

one year. They were deficient in calcium,
vitamin D, and had lower BMD than controls.
Then treated and untreated subjects given diet
and supplements for one year. GFD compliant

B

subjects taking supplements had a 35%
increase in BMD, but gain was less in
non-adherent subjects.

GFD group A; and GFD & 4
Effect of zoledronic acid on bone
Kumar (2013) [39]

mg zoledronic acid, calcium

n = 13 (11 completes), and n = 15

Significant improvement in clinical,

mineral density in patients of celiac

Randomized,

(1000 mg) and

M/F = 7/6 and 7/8,

biochemical parameters in both groups; GFD

disease: a prospective, randomized,

prospective

cholecalciferol (0.6 million

Mean age 28.2 ± 12.8 years; 25.3 ± 9.1

with Zoledronic acid was not found to be

units) if serum vitamin D

years

better than GFD alone after one year.

pilot study

was low, group B

A
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Author Publication Year
Kurppa (2014) [40]

Summary
Title

Design

Treatment

Participants

Results

Quality

Benefits of a gluten-free diet for

Prospective,

Unrestricted and GFD

n = 40 randomized to GFD group or

There were no differences between groups in

A

asymptomatic patients with

cohort, RCT

unrestricted group, n = 20 (M/F = 15/5),

laboratory test results, BMD (lumbar spine

n = 20 (11/9), Mean age: 42 (21–74)

and femur neck), or body composition. Most

years GFD, Mean age: 42 (21–74)

measured parameters (GI symptoms, psych

years, unrestricted diet

well-being, and SF-36 QOL) improved when

serologic markers of celiac disease.

patients in the gluten-containing diet group
were placed on GFDs.
Pantaleoni (2014) [4]

Bone mineral density at diagnosis

Prospective

of celiac disease and after 1 year of

cohort

gluten-free diet.

GFD

(M/F) n = 146/23 Mean age:

Stratification of patients according to sex and

38.9 ± 12.6 years,

age showed a higher prevalence of low bone

pre/post-menopausal = 104/42

mineral density in men older than 30 years

A

and in women of all ages. GFD led to
a significant improvement in lumbar spine
and femoral neck mean T-score value

CD: celiac disease; F: female, M: male; BMD: bone mineral density; GFD: gluten-free diet; PA: physical activity; DXA: dual-energy X-ray absorptiometry; BMI: body
mass index; FU: follow-up; SF-36 QOL: standard quality of life index; yr.: year; Quality assessment was performed by the author according to STROBE recommendations.
RANKL: receptor activator of nuclear factor-κB ligand; PTH: parathyroid hormone; IGF-1: Insulin-like growth factor 1; PA: Physical activity.
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Various tests are used to measure bone density, including the DXA, quantitative computed
tomography (QTC), photon absorptiometry, and ultrasound. Adult bone mineral loss is categorized into
osteopenia and osteoporosis. The World Health Organization (WHO) has established DXA as the best
densitometry technique for the measurement of bone density in postmenopausal women, but the
sensitivity of the DXA is lower compared to QTC in individuals with celiac disease [41]. A T-score between
−1 and −2.5 and ≤2.5 indicates bone mineral loss with a greater than average risk of fracture [12]. Multiple
risk factors and the results of the DXA scan are good predictors of relative fracture risk, and prediction
is enhanced when co-morbidities, such as celiac disease, are added to the FRAX (WHO Fracture Risk
Assessment Tool) index [42].
3.1. Diet Therapy
The studies reviewed that reported a dietary compliance measure demonstrated that adherence to the
GFD has a positive effect on bone mineral density [4,36,38,43]. The greatest diet treatment gain occurs
in the first year of in longitudinal studies that followed individuals for more than 12 months [27,34,37].
But full recovery for adults was mainly achieved after 5 years [27]. Newly diagnosed older adults benefit
from the GFD with significant gains in femoral and lumbar spine being reported in the first year of
treatment [35,36]. Malabsorption associated malnutrition delayed restoration of BMD in a vitamin D
and calcium supplemented high risk group, while less nutritionally compromised individuals in the same
study progressed from osteoporosis to osteopenia by one year of treatment [33]. Bone turnover markers
Interleukin-18 (IL-18), Interleukin-6 (IL-6), and N-terminal telopeptide of procollagen type I were
measured in treated (n = 25), untreated individuals (n = 17), and controls (n = 21) [30]. The GFD group
had reduced levels of IL-18 and a lower RANKL/osteoprotegerin (OPG) ratio compared to untreated
subjects, while the N-terminal telopeptide of procollagen type I was comparable to controls. Another
study looked at the regulation of osteoclastogenesis and bone turnover in celiac disease in a cohort study
of healthy premenopausal female subjects and diet compliant individuals with celiac disease who had no
evidence of hypoparathyroidism [44]. The authors reported that the OPG/RANKL ratio was significantly
lower in CD patients than in controls (14.8 ± 6.9 vs. 19.4 ± 9.2; p < 0.05).
Overall, the studies have shown that a GFD for the majority of patients is an effective therapy for
long-term bone mineral recovery. The use of intermediate measures such as BMD, quality of life, and
bone turnover, is more practical than fracture reduction estimates because these studies followed patients
for one to five years. The incidence of fractures in a group of diet compliant participants (n = 265,
M/F = 422/223) before and 5 years after diagnosis was compared to a cohort of patients with functional
gastrointestinal disorders (n = 530, M/F = 84/446) [45]. The incidence of fractures declined after
treatment (Incidence Rate (IR) = −1.22 events per 1000 patients year−1) and Health Risk (HR) of fracture
was comparable to controls (HR: 1.28, 95% CI: 0.74–2.21, p = ns), thus confirming the long-term benefit
of the GFD.
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Figure 1. Selection process for studies included in the systematic review.
3.1.1. GFD and Nutrient Supplementation
The review identified 3 articles that addressed the treatment effects of vitamin and mineral
supplementation on BMD [25,26,33]. The approach of Ciacci, et al. was a constant dietary calcium level
of 1250 mg daily with diet alone or the addition of a supplement for those who were intolerant to
lactose [25]. There was no significant change in vitamin D, urinary calcium increased, and a significant
increase in BMD in the lumbar spine, femoral neck, and Ward’s triangle in this study. Non-responders
were more likely to be older and menopausal. Mautalen and associates randomized participants to
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a gluten-free diet condition (n = 7) or diet plus calcium (1.0 g day−1) and vitamin D (32,000 IU week−1)
(n = 7) [26]. This trial’s results were compromised by non-compliance. Adherent subjects had significant
gains in BMD compared to patients that with frequent lapses, and improvement favored the axial compared
to the peripheral skeleton. Lastly, Papamichael, et al. observed serum 25(OH)D3, parathyroid
hormone (PTH), and calcium before and after treatment [33]. Only women with severe malabsorption
were given supplements, the rest of the study group relied on the GFD and sunshine. In summary, the
effect of supplementation depends on the disease severity at diagnosis and environmental exposure to
UV radiation. The BMD of the majority of patients improved significantly to adequate vitamin D and
calcium in the first year.
Satenga-Guidetti, et al. evaluated the pre- and post-treatment nutrient status of subjects (n = 86) on
a GFD with no supplementation with serum folate, 25OH-D, hemoglobin, transferrin, and albumin
measurement, as well as urinary calcium [29]. The researchers observed after a one-year follow-up that
34% of 86 newly diagnosed CD patients had a normal bone mineral density, while 40% had osteopenia
and 26% osteoporosis with dietary treatment. There were no differences between gender in bone metabolism
markers or most nutritional indices. The only difference was between pre- and post-menopausal women,
where BMD and several bone metabolic markers were significantly different. This is in contrast to
another study where reduced BMD was found after complete healing of duodenal lesions in one half of
their patient sample [46]. The researchers concluded that additional measures beyond dietary compliance
and counseling should be taken into account in order to increase BMD.
Treatment failure may actually be the result of a highly processed GFD as it is associated with small
bowel bacterial overgrowth (SIBO) [47]. A highly processed GFD has been shown to alter the gut
microbiome and increase GI symptoms which leads to an increased permeability of the epithelial barrier
in patients with CD [48–50]. The health of the gut microbiota and the symptoms related to SIBO impact
normalization of bone metabolism. The GFD does not reduce the risk of serious co-morbidities such as
small bowel adenocarcinoma, Enteropathy-Associated T-cell Lymphoma (EATL), abortions,
myocardial infarction, colonic adenocarcinoma, gastric MALT-lymphoma, ulcerative jejuno-ileitis,
Cholangitis, severe non-alcoholicsteato-hepatitis, and autoimmune thrombocytopenia [51].
Nutritional status at time of diagnosis, age, menopausal status, environment, and dietary compliance
moderate the effect of dietary supplements on BMD. Controversy exists regarding the amount of
supplementation required to reverse malnutrition for key nutrients. A large clinical trial comparing the
constant vitamin D and calcium dietary approach to a GFD without supplementation is needed. Because
the maintenance of serum vitamin D is improved in the presence of adequate calcium intakes and high
levels of physical activity, the study should collect direct measures of total UV radiation exposure and
physical activity [52].
3.1.2. GFD and Bisphosphonates
The use of hormone replacement therapy or bisphosphonates, has been shown in healthy pre- and
post-menopausal women to be effective in restoring bone mass; and the data suggests that combining
these therapies with weight-bearing exercise may have additive effects [53,54]. A small pilot study
(n = 28) treating CD patients with either GFD and zoledronic acid, or a calcium and cholecalciferol
supplemented GFD reported that there were no significant difference in effectiveness [39]. Replication
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of this study with a larger sample size that includes older adults may be more representative of the adult
CD population.
3.1.3. GFD and Physical Activity
Few researchers have studied the effect of physical activity on bone density in this population.
Passananti and associates studied two groups of women (20–60 years), and compared baseline measures
for the International Physical Activity Questionnaire (IPAQ), fatigue visual analogue scale (VAS),
dietary compliance, gastrointestinal symptoms, serum vitamin D, anti-transglutaminase antibodies
(U mL−1), and BMD in 2 or 5 year follow-up cohorts [37]. Women who were taking oral contraceptives
or hormone replacement therapy were excluded. A total of 110 participants were enrolled into the study,
but 15 were either lost to follow-up or did not adhere to the GFD. The final sample size of the
two cohorts were n = 48, n = 47, for the 2 and 5 year follow-up cohorts respectively. BMD measurements
were taken at the right femur and lumbar spine. Chi-square tests were used for categorical data and
ANOVA for continuous measures. Baseline and follow-up (FU) BMD was analyzed by two-sample and
pairwise t-tests with a confidence interval set at 95%. Health measures also included BMI, small intestine
pathology using Marsh categories for lesion comparisons and age of menarche and menopause. In the
2-year FU group 53.7% of participants reported low physical activity, and 10.6% were highly active
(IPAQ = 3). Compared to baseline fatigue in this group, there was no statistical difference. The 5-year
FU group was more active, with 46.3% reporting low levels and 14.6% highly active. Yet, the active
subjects in in this group were more likely to report fatigue (p = 0.039 post hoc). The mean IPAQ score
for both groups were not significantly different (1.60 ± 0.67 vs. 1.87 ± 0.88; p > 0.05). There was no
significant difference between groups at FU for BMD and no relationship between BMD and intensity
of Physical activity (PA) (p > 0.05 at the lumbar spine and proximal femur). The researchers concluded
that physical activity has a minor role in supporting the bone mineral recovery in celiac patients. It is
important to note that the study participants had normal vitamin D levels, but did not meet their dietary
needs for calcium.
Di Stefano (2000) observed lifestyle factors in untreated patients with CD and BMD [55]. The
participants (n = 39) were drawn from a consecutive patient pool with a spectrum of gluten-sensitive
disorders: classical celiac, herpetiformis dermatitis, subclinical, or refractory (non-responsive) sprue.
The independent variables were gender, smoking status, symptom severity, symptom duration,
sunlight exposure, and level of physical activity. PA level was determined by self-report of occupational,
recreational (cycling and brisk walking), and activities of daily living on a 0–4 scale of frequency [56].
Predictors of BMD were gender, malnutrition, severity, and PA. Symptom severity predicted low BMD
in lumbar and femoral neck (−2.5 ± 0.8, p < 0.001). PA was correlated with BMD at the lumbar
(r = 0.57, p < 0.004) and femoral (r = −0.71, p < 0.004); and bone mineral content (BMC) was correlated
with lumbar BMC (r = 0.59, p < 0.001) and femoral BMC (r = 0.58, p < 0.001).
Studies concur that fatigue and celiac symptoms impact the frequency and intensity of exercise. The
outcome measures, whether biochemical or radiologic, do not take muscle strength or flexibility
into account. No direct measure of fitness level or every-day movement has been published. Aside from
a study by Gonzalez et al. [57], few papers have identified overall body composition changes in spite of
observations that treatment results in obesity in some patients [58,59]. In the elderly the impact of
exercise on biochemical pathways involved in bone remodeling, such as receptor activator of nuclear
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factor-κB (RANK) /RANKL/OPG, is positive and particularly responsive to specific types of exercise
(e.g., high or low impact exercise and resistance training) [60]. It has been observed that individuals with
CD have an altered osteoprotegerin/RANKL ratio, which may also predispose patients to cardiovascular
disease [44,61] Future health intervention research in celiac disease should focus on improving wellness,
strength, and functional capacity in this population.
A randomized, double-blinded vs. placebo parallel study of the effectiveness of L-carnitine on fatigue
in patients with celiac disease [62]. Participants were given a placebo or 2 g L-carnitine daily
for 180 days. L-carnitine plays an important role in muscle contraction and energy production. The
experimental group experienced an increase in organic cation transporter 2 (OCTN2), a sodium-dependent
transporter for carnitine that facilitates carnitine absorption, as well as amines, some vitamins. The
L-carnitine treatment group reported significant improvement in fatigue, as evaluated by the VAS scale.
The rise in OCTN2 might explain this change. Ultimately, low levels of physical activity in persons with
CD may be improved through L-carnitine treatment, which may aid in stimulation of bone
mineral deposition.
The specific type of exercise may be a critical factor for improving bone health. Marques and
associates studied the effect of resistance and moderate-impact aerobics training protocols on proximal
femur BMD, muscle strength, balance, body composition, serum OPG, and RANKL levels in older
women (n = 71). After eight months of the intervention, only the resistance training group experienced
positive changes in BMD and muscle strength [63]. Both protocols had significant effects on functional
balance control, a key factor in fall prevention. A later study by this author observed the effect of combined
impact training for balance and lower-extremity muscle strength in men and women; the researchers
reported improvement in dynamic balance (6.4%), muscle strength (11.0%) and trochanter (0.7%),
intertrochanter (0.7%), total hip (0.6%), and lumbar spine BMD (1.7%), while osteocalcin, OPG and
RANKL levels remained unchanged [64]. Exercise performed with adequate dose and intensity addresses
multiple risk factors for osteoporosis and fractures. Further research on celiac disease lifestyle intervention
should begin with known barriers to PA and motivational therapies in other populations [65].
3.1.4. Nutritional Deficiencies, Dietary Sodium, Dysbiosis, and Inflammation
Folate supplementation is an effective treatment for elevated homocysteine in CD [66]. B12 and iron
deficiency is a common symptom in untreated CD and in one study it was discovered in 41% of
participants [67]. Dahele and Ghosh reported that after oral and parenteral administration of B12, all
patients (n = 39) had normal serum levels of B12 at one year follow-up. A new role for B12 in bone
health has been demonstrated in a mouse model of B12 deficiency demonstrating that deficiency impairs
taurine synthesis and enhances Growth hormone-dependent IGF-1 synthesis in the liver; this subsequently
increases osteoblast function (Figure 1) [68]. Research in humans should focus on reevaluating
vitamin B12 requirements in CD to determine its role in bone remineralization.
Intestinal microbiota has been implicated in the development of CD which may not be corrected
after treatment. Due to the low level of phylum Bacteroides and abundance of Firmicutes in the stools
of people with CD, this imbalance has a pro-inflammatory effect by increasing IL-10 cytokine [69]. The
GFD did not normalize gut bacteria in one two-year follow-up study of children with CD, and has been
shown to induce dysbiosis in healthy adults fed a gluten-free diet for one month [50,70]. Vitamin D
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metabolite 25(OH)2D3 has been shown in one vitro study to prime dendritic cells to induce regulatory T
(Treg) cells [71]. In that study, the results showed that Dermal dendritic cell-derived IL-10 induce
IL-10+ TR1 cells. Gut microbiota also affects T cell differentiation and host susceptibility to
autoimmune disease [72]. Bifidobacterium genus is low in the stools of celiac patients on a GFD
compared to healthy controls consuming a regular diet. This genus has been shown to protect against
inflammation and mucosal damage caused by gliadin peptides in vitro [73].
A change in diet can bring about long-term improvement in chronic inflammation and malabsorption
of nutrients due to alterations in the gut microbiome [74]. Enhanced barrier function due to diet and
physical activity was shown in a study of professional elite rugby players eating a diet high in
whey protein, fruits, and vegetables during training camp [75]. The DNA from fecal samples showed a
rich diversity of organism such as phylum Firmicutes, genus Akkermansia, and fewer Bacteroides than
in two less active controls groups comprised of normal weight and obese individuals.
The conclusion of a multivariate analysis of factors predicting recovery in 30 women and 11 men w
with CD as that gender (women), pretreatment age, and pretreatment BMD independently predict
bone mineralization, especially in the lumbar spine [25]. The regression coefficient for lumbar spine
BMD (+0.060 to +0.160 g cm−2) did not overlap the 95% confidence interval. The authors identified in
their discussion that vitamin D3 supplementation may be an important factor that was not addressed in
their study. In a double blind placebo controlled study, Fickling and associates (2001) administered 300,000
units of choiecalciferol (vitamin D) by intramuscular injection or saline placebo to newly diagnosed CD
patients [76]. Data was collected at 6, 12, and 24 months. Both groups saw improvements in BMD, but
no significant difference was found between groups.
A case report of a woman with severe bone mineral loss illustrates the need for individualized
treatment of CD [14]. A 37-year-old, sedentary woman diagnosed with CD initially had a low BMD
and was prescribed calcium (1000 mg day−1) and vitamin D (400 IU day−1). After one year a Registered
Dietitian-Nutritionist verified diet compliance, serum vitamin D remained low (33 nmol L−1), and the dose
was subsequently increased to 1000 IU day−1. After an 81% increase in the spine and 60% change in the hip
at year 3, her bone mass plateaued by year 4. This demonstrates the need to evaluate lifestyle, nutrition, and
bone status throughout treatment.
A 10-year study of individuals with CD reported that more than half suffered from vitamin
deficiencies in folate, B12 and B6, as evidenced by elevated homocysteine levels, low plasma folate,
and B6 [77]. In a Dutch study of newly diagnosed adults (n = 80), researchers observed deficiencies in
vitamin A, B6, folic acid, B12, and zinc in 67% of participants [78]. B12 and iron deficiency are common in
untreated CD and in one study it was discovered in 41% of participants [67]. Dahele and Ghosh reported that
after oral and parenteral administration of B12, all patients (n = 39) had normal serum levels of B12 at one
year follow-up [67]. A new role for B12 in bone health has been shown in a mouse model of B12 deficiency
demonstrating that deficiency impairs taurine synthesis and enhances growth hormone-dependent IGF-1
synthesis in the liver; this subsequently increases osteoblast function [68]. Research in humans should focus
on reevaluating vitamin B12 requirements in celiac disease to determine its role in bone remineralization.
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4. Discussion
Our understanding of bone mineral metabolism and the impact of diet and exercise in the treatment
of bone mineral loss for people with celiac disease is incomplete. For this review, the author identified
published works and most of these were small, non-randomised clinical trials. Because most participants
were recruited from University hospitals and specialty treatment centers, the results may be subject to
sampling bias. In spite of an exhaustive search only two studies were found using randomised control,
and these did not use an intention-to-treat analysis in spite of subject attrition. Studies also lacked
uniformity in dietary intake and compliance assessment measures. It is critical to develop a database of
individual raw data from studies on bone density and celiac disease so that a meta-analysis of individual
participant data can be published [79]. This type of analysis can differentiate treatment effects for
different sub-groups, such as non-responders. The incidence of CD continues to rise in all ages groups,
creating need for better management of low BMD in adults and elderly [80].
Nutrient malabsorption due to chronic inflammation and villus atrophy are thought to be the major
causes of low BMD (Figure 2). In bone, calcium is regulated by parathyroid hormone (PTH),
1,25-dihydroxyvitamin D (Vitamin D3), and calcitonin [81]. Hyperparathyroidism is common in
untreated celiac disease and is characterized by high bone turnover and cortical bone loss [82].
In addition, alterations in gallbladder function, exocrine pancreatic insufficiency, and gut permeability
reduce the absorption of essential nutrients [83]. BMD is directly related to the extent of villus atrophy
which results in malabsorption of calcium, iron, vitamin D, and folic acid [84]. Even after long after the
initiation of diet treatment calcium absorption may be reduced [85]. When administered with vitamin D,
Vitamin K has been shown to increase BMD in osteoporosis and reduce fracture rates due to its role in
calcium balance [86].
Bone is dynamic tissue that is continuously going through resorption and absorption of calcium from
blood to bone in a process called remodeling (Figure 3). The loss of bone density in CD is caused by
an imbalance in osteoclastogenesis and osteoblast activity as reported from a study on newly diagnosed
patients compared to individuals on a GFD [30]. The authors reported that proinflammatory factors,
N-terminal telopeptide of procollagen type I and IL-6, were higher in the untreated CD group, thus
suggesting that bone-turnover regulating factors contributed to the reduced bone mass. Other
inflammatory factors involved in the pathogenesis of bone metabolism are osteoprotegerin (OPG), a
member of the tumor necrosis factor receptor family, and RANKL. RANKL is a cytokine that stimulates
osteoclast formation and activation in bone, while OPG acts as a decoy receptor for RANKL, thereby
controlling its function. The OPG/RANKL ratio was significantly lower in CD patients in a controlled study
of premenopausal women than age matched controls, and the OPG/RANKL ratio was correlated with loss
of BMD at the spine [44]. Demographic and lifestyle factors such as age, gender, eating disorders,
alcohol abuse, low physical activity, and smoking are also associated with low BMD in CD [55,80,87].
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5. Conclusions
The most important behavior impacting bone density in celiac disease is diet adherence. The
psychological determinants of GFD adherence, such as self-discipline, values, depression, anxiety, and
presence of other food intolerances may have an effect on bone rehabilitation [88]. Patients who struggle
with personality and psychological barriers to diet compliance may benefit from motivational interviewing
techniques early in treatment [89]. Adults diagnosed with celiac disease may have malabsorption of
long-standing, therefore may benefit from iron, folate, B12, vitamin D3, vitamin K, calcium, magnesium
and docosahexaenoic acid (DHA) therapy [66,77,90]. The nutrient density shortcomings of the
gluten-free diet call for the early and individualized services of a registered dietitian-nutritionist with
celiac disease expertise in both medical nutrition therapy and lifestyle coaching [91].
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